Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
- PMID: 29599478
- PMCID: PMC5876407
- DOI: 10.1038/s41467-018-03421-7
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
Abstract
Nicotinamide adenine dinucleotide (NAD+) has emerged as a critical co-substrate for enzymes involved in the beneficial effects of regular calorie restriction on healthspan. As such, the use of NAD+ precursors to augment NAD+ bioavailability has been proposed as a strategy for improving cardiovascular and other physiological functions with aging in humans. Here we provide the evidence in a 2 × 6-week randomized, double-blind, placebo-controlled, crossover clinical trial that chronic supplementation with the NAD+ precursor vitamin, nicotinamide riboside (NR), is well tolerated and effectively stimulates NAD+ metabolism in healthy middle-aged and older adults. Our results also provide initial insight into the effects of chronic NR supplementation on physiological function in humans, and suggest that, in particular, future clinical trials should further assess the potential benefits of NR for reducing blood pressure and arterial stiffness in this group.
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans.Am J Clin Nutr. 2020 Aug 1;112(2):413-426. doi: 10.1093/ajcn/nqaa072. Am J Clin Nutr. 2020. PMID: 32320006 Free PMC article. Clinical Trial.
-
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults.Sci Rep. 2019 Jul 5;9(1):9772. doi: 10.1038/s41598-019-46120-z. Sci Rep. 2019. PMID: 31278280 Free PMC article. Clinical Trial.
-
Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men.J Physiol. 2020 Feb;598(4):731-754. doi: 10.1113/JP278752. Epub 2019 Dec 26. J Physiol. 2020. PMID: 31710095 Clinical Trial.
-
Balancing NAD+ deficits with nicotinamide riboside: therapeutic possibilities and limitations.Cell Mol Life Sci. 2022 Aug 2;79(8):463. doi: 10.1007/s00018-022-04499-5. Cell Mol Life Sci. 2022. PMID: 35918544 Free PMC article. Review.
-
The use of Nicotinamide and Nicotinamide riboside as an adjunct therapy in the treatment of glaucoma.Eur J Ophthalmol. 2023 Sep;33(5):1801-1815. doi: 10.1177/11206721231161101. Epub 2023 Mar 14. Eur J Ophthalmol. 2023. PMID: 36916064 Review.
Cited by
-
Sex-specific alterations in NAD+ metabolism in 3xTg Alzheimer's disease mouse brain assessed by quantitative targeted LC-MS.J Neurochem. 2021 Oct;159(2):378-388. doi: 10.1111/jnc.15362. Epub 2021 Apr 28. J Neurochem. 2021. PMID: 33829502 Free PMC article.
-
Mitochondrial contributions to vascular endothelial dysfunction, arterial stiffness, and cardiovascular diseases.Am J Physiol Heart Circ Physiol. 2021 May 1;320(5):H2080-H2100. doi: 10.1152/ajpheart.00917.2020. Epub 2021 Apr 9. Am J Physiol Heart Circ Physiol. 2021. PMID: 33834868 Free PMC article. Review.
-
New Crystalline Salts of Nicotinamide Riboside as Food Additives.Molecules. 2021 May 6;26(9):2729. doi: 10.3390/molecules26092729. Molecules. 2021. PMID: 34066468 Free PMC article.
-
MCART1/SLC25A51 is required for mitochondrial NAD transport.Sci Adv. 2020 Oct 21;6(43):eabe5310. doi: 10.1126/sciadv.abe5310. Print 2020 Oct. Sci Adv. 2020. PMID: 33087354 Free PMC article.
-
A Perspective and Framework for Developing Sample Type Specific Databases for LC/MS-Based Clinical Metabolomics.Metabolites. 2019 Dec 21;10(1):8. doi: 10.3390/metabo10010008. Metabolites. 2019. PMID: 31877765 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials